Grand Rounds: Advances in Cystic Fibrosis Care
04-18-2025
By Robert Abood, MD, and Heather Strawbridge, MD. , Co-Directors, Lewis H Walker, MD Cystic Fibrosis Center, Akron Children's, Akron, OH
More about Heather Strawbridge, MD
More about Robert Abood, MD, FAAP
Objectives (Educational Content) :
1. Describe the genetics and pathophysiology cystic fibrosis and identify some of the clinical manifestations. 2. Recognize the advances in cystic fibrosis that have led to improved survival. 3. Examine currently available modulator therapies and assess possible future treatments.
Target Audience:
General pediatricians, family physicians, nurse practitioners, physician assistants, social workers, psychologists, and nurses.
Identified Gap:
Through highlighting the significant advancements in improved diagnostic techniques to innovative treatments targeting the underlying genetic causes of the disease, patients living with cystic fibrosis are experiencing better survival rates and quality of life. Addressing these care gaps requires efforts to improve healthcare access, affordability, and continued research into comprehensive treatments for cystic fibrosis.
Estimated Time to Complete the Educational Activity:
1 hour(s)
Expiration Date for CE/CME Credit:
04-17-2026
Method of Participation in the Learning Process:
The learner will view the presentation, successfully complete a post-test and complete an activity evaluation.
Evaluation Methods:
All learners must successfully complete a post-test, as well as an activity evaluation, to claim CE/CME credit.
Disclosure:
The following presenter has indicated that there are no financial relationships with any ineligible companies: Robert Abood, MD. Heather Strawbridge, MD. The following planning committee member has indicated that a financial relationship with an ineligible company: All relationships have been mitigated. The remaining planning committee/CME committee members have indicated that they have no financial relationships with any ineligible companies.
Accreditation Statement:
Akron Children’s Hospital is accredited by the Ohio State Medical Association to provide continuing medical education for physicians.
Akron Children’s Hospital designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Bibliography:
1. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation. Am J Resp Crit Care Med 2013;187(11):1219-1225.
2. Keating C, Yonker LM, Vermeulen F, et al. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomized, active-controlled, phase 3 trials, Lancet Resp Med 2025;13:256-71.
3. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele, New Engl J Med 2019;381:1809-19.
